covid-19 mrna vaccine
Vaccineexperimental
Clinical trial activity
16 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
6
Phase 3
1
Phase 4
1
Earliest trial started Nov 29, 2021 (NCT05144139)
Timeline
Indications
Approved for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07215520 | Phase 2 | Nov 3, 2025 | CastleVax Inc. |
| NCT06680375 | Phase 2 | Nov 11, 2024 | GlaxoSmithKline |
| NCT06374394 | Phase 3 | Apr 29, 2024 | GlaxoSmithKline |
| NCT05938075 | Phase 1 | Aug 4, 2023 | Medical Research Council, South Africa, Perinatal HIV Research Unit, Baragwanath |
| NCT05886790 | N/A | May 30, 2023 | People's Liberation Army of China, Xiamen University |
| NCT05855408 | Phase 4 | May 18, 2023 | Government of China |
| NCT05609045 | Phase 1 | Dec 31, 2022 | Wuhan Recogen Biotechnology Co., Ltd., Wuhan Rhegen Biotechnology Co., Ltd. |
| NCT05596734 | Phase 1 | Oct 28, 2022 | Biontech, Pfizer |
| NCT05568693 | N/A | Sep 21, 2022 | Sichuan University |
| NCT05366296 | Phase 1 | Jul 31, 2022 | Wuhan Recogen Biotechnology Co., Ltd. |
| NCT05373472 | Phase 2 | Jul 6, 2022 | Capital Medical University, Government of China, Hebei University, Tianjin Cansino Biotechnology Inc |
| NCT05439824 | Phase 2 | Jun 28, 2022 | Government of China, Shijiazhuang Pharma Group (CSPC) |
| NCT05354063 | Phase 1 | Jun 1, 2022 | Hangzhou Hospital of Traditional Chinese Medicine, Nanjing University, Shijiazhuang Pharma Group (CSPC) |
| NCT05373485 | Phase 1 | May 20, 2022 | Capital Medical University, Government of China, Hebei University, Tianjin Cansino Biotechnology Inc |
| NCT05354089 | Phase 1 | Apr 27, 2022 | Hangzhou Hospital of Traditional Chinese Medicine, Nanjing University, Shijiazhuang Pharma Group (CSPC) |
| NCT05144139 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2021 | Mahosot Hospital, Stemirna Therapeutics |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 1 | 3 | 2022 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 3 | 3 | 2 | 2022 |
| Capital Medical University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2024 |
| Hangzhou Hospital of Traditional Chinese Medicine | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Hebei University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Nanjing University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Tianjin Cansino Biotechnology Inc | For profit | 2 | 2 | 2 | 2022 |
| Wuhan Recogen Biotechnology Co., Ltd. | For profit | 2 | 1 | 1 | 2022 |
| Biontech | For profit | 1 | 1 | 1 | 2022 |
| CastleVax Inc. | For profit | 1 | 1 | 1 | 2025 |
| Mahosot Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Medical Research Council, South Africa | Government | 1 | 0 | 1 | 2023 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2023 |
| Perinatal HIV Research Unit, Baragwanath | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Pfizer | For profit | 1 | 0 | 1 | 2022 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Stemirna Therapeutics | For profit | 1 | 1 | 1 | 2021 |
| Wuhan Rhegen Biotechnology Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Xiamen University | Academic/Hospital | 1 | 1 | 1 | 2023 |
20 organizations
Page 1 / 1